An observational study in Atrial Fibrillation and Atrial Flutter, sponsored by Brazilian Clinical Research Institute. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-04.
Sponsored by Brazilian Clinical Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Atrial Fibrillation with a site in Argentina — 5 open to participants now, 6 under way, 2 of them phase 3. Atrial Fibrillation · Argentina.
Among the 45 studies in Atrial Fibrillation with a site in Argentina, this one is the 5th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2020, is one of 12 observational ones, and was the 36th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →5 of the 45 studies in Atrial Fibrillation with a site in Argentina are open now. Recruiting first, the newest first:
School of Medicine. National University of Cuyo · Sites in Argentina
Ages 18–80
Regeneron Pharmaceuticals · Sites in Argentina, United States, Brazil and 1 more country
Ages 18+
Cardiovascular Research Center Rosario British Sanatorium · Sites in Argentina
Ages 65+ · Healthy volunteers
Anthos Therapeutics, Inc. · Sites in Argentina, United States, Brazil and 32 more countries
Ages 65+
Population Health Research Institute · Sites in Argentina, United States, Australia and 15 more countries
Ages 55+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 25 · Phase 4 3
First in 2001; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,016 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 2,437 across the 32 interventional studies, 1,266 across the 12 observational. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 45 have an industry lead sponsor. The 10 most frequent:
Brazilian Clinical Research Institute is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Brazilian Clinical Research Institute has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
2 of the studies in Atrial Fibrillation with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07175428Regeneron PharmaceuticalsSafety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | 2027-02-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 45 studies in Atrial Fibrillation with a site in Argentina, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Follow a representative sample of Latin American patients diagnosed with atrial fibrillation to set data on demographic characteristics, documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death
Patients will be followed 6 months and 1 year after the baseline visit and will be collected data of antithrombotic therapy, laboratory data, discontinuation rates of antithrombotic therapy and clinical outcomes.
Patient with Atrial Fibrilation or Atrial Flutter
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.
INR control rate
Time frame: 12 months
Oral anticoagulation discontinuation rate
Time frame: 12 months
Percentage of death
Time frame: 12 months
Percentage of stroke
Time frame: 12 months
Percentage of systemic embolism
Time frame: 12 months
Percentage of myocardial infarction
Time frame: 12 months
Percentage of major bleeding
Time frame: 12 months
Percentage of electrical cardioversion
Time frame: 12 months
Percentage of percutaneous ablation of AF
Time frame: 12 months
Percentage of atrioventricular junction ablation
Time frame: 12 months
Percentage of patients that need of pacemaker implantation
Time frame: 12 monts
Percentage of other cardiovascular hospitalization
Time frame: 12 months
Plan to share: Yes
Supporting information: Study protocol, Informed consent form, Clinical study report
No publications or documents are linked to this record.
Ran from Aug 2020 to primary completion in Sep 2024, 49 months.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 49 months is close to that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brazilian Clinical Research Institute